Skip Navigation
Skip to contents

Diabetes Metab J : Diabetes & Metabolism Journal

Search
OPEN ACCESS

Search

Page Path
HOME > Search
3 "Ho Cheol Hong"
Filter
Filter
Article category
Keywords
Publication year
Authors
Funded articles
Original Articles
Adipose Gene Expression Profiles Related to Metabolic Syndrome Using Microarray Analyses in Two Different Models
Hye Jin Yoo, Hwan-Jin Hwang, Tae Woo Jung, Ja Young Ryu, Ho Cheol Hong, Hae Yoon Choi, Sei Hyun Baik, Kyung Mook Choi
Diabetes Metab J. 2014;38(5):356-365.   Published online October 17, 2014
DOI: https://doi.org/10.4093/dmj.2014.38.5.356
  • 4,866 View
  • 48 Download
  • 7 Web of Science
  • 7 Crossref
AbstractAbstract PDFPubReader   
Background

Peroxisome proliferator-activated receptor-γ (PPAR-γ) agonist has a wide-ranging influence on multiple components of metabolic syndrome. The Otsuka Long-Evans Tokushima Fatty (OLETF) rat is a useful animal model of metabolic syndrome. To determine genes related to metabolic syndrome, we examined overlapping genes that are simultaneously decreased by PPAR-γ agonists and increased in OLETF rats using microarrays in two different models.

Methods

In the first microarray analysis, PPAR-γ agonist-treated db/db mice were compared to standard diet-fed db/db mice. In the second microarray analysis, OLETF rats were compared to Long-Evans Tokushima Otsuka (LETO) rats (control of OLETF rats).

Results

Among the overlapping genes, in the present study, we validated that lipocalin-2 expression was significantly decreased in the visceral adipose tissue of PPAR-γ agonist-treated db/db mice compared to standard diet-fed db/db mice and increased in OLETF rats compared to LETO rats using real time reverse transcription polymerase chain reaction. Furthermore, we showed for the first time that lipocalin-2 expression was significantly increased in the visceral adipose tissues of obese humans compared with nonobese humans. In addition, the expression level of lipocalin-2 in human visceral adipose tissue had a significant positive correlation with body mass index, serum interleukin-6, adipocyte fatty acid binding protein levels, and white blood cell count.

Conclusion

Lipocalin-2 was confirmed to be a significant adipokine affected by PPAR-γ agonist and obesity in the present study. Also, for the first time in human visceral adipose tissue, it was determined that the expression of lipocalin-2 from obese humans was significantly increased and correlated with circulating inflammatory markers.

Citations

Citations to this article as recorded by  
  • Lipocalin‐2—The myth of its expression and function
    Dahui Li, Wai Yan Sun, Bowen Fu, Aimin Xu, Yu Wang
    Basic & Clinical Pharmacology & Toxicology.2020; 127(2): 142.     CrossRef
  • Lipocalin-2 counteracts metabolic dysregulation in obesity and diabetes
    Ioanna Mosialou, Steven Shikhel, Na Luo, Peristera Ioanna Petropoulou, Konstantinos Panitsas, Brygida Bisikirska, Nyanza J. Rothman, Roxane Tenta, Bertrand Cariou, Matthieu Wargny, Elisabeth Sornay-Rendu, Thomas Nickolas, Mishaela Rubin, Cyrille B. Confav
    Journal of Experimental Medicine.2020;[Epub]     CrossRef
  • Metabolism and adult neurogenesis: Towards an understanding of the role of lipocalin-2 and iron-related oxidative stress
    Ana Catarina Ferreira, Nuno Sousa, João M. Bessa, João Carlos Sousa, Fernanda Marques
    Neuroscience & Biobehavioral Reviews.2018; 95: 73.     CrossRef
  • LH-21, A Peripheral Cannabinoid Receptor 1 Antagonist, Exerts Favorable Metabolic Modulation Including Antihypertensive Effect in KKAy Mice by Regulating Inflammatory Cytokines and Adipokines on Adipose Tissue
    Ziqi Dong, Hui Gong, Yadan Chen, Hong Wu, Jun Wu, Yinghong Deng, Xinmao Song
    Frontiers in Endocrinology.2018;[Epub]     CrossRef
  • Lipocalin 2 produces insulin resistance and can be upregulated by glucocorticoids in human adipose tissue
    Prasad G. Kamble, Maria J. Pereira, Cherno O. Sidibeh, Sam Amini, Magnus Sundbom, Joey Lau Börjesson, Jan W. Eriksson
    Molecular and Cellular Endocrinology.2016; 427: 124.     CrossRef
  • Serum lipocalin-2 levels are positively associated with not only total body fat but also visceral fat area in Chinese men
    Yuqi Luo, Xiaojing Ma, Xiaoping Pan, Yiting Xu, Qin Xiong, Yunfeng Xiao, Yuqian Bao, Weiping Jia
    Medicine.2016; 95(30): e4039.     CrossRef
  • From the periphery to the brain: Lipocalin-2, a friend or foe?
    Ana C. Ferreira, Sandro Dá Mesquita, João C. Sousa, Margarida Correia-Neves, Nuno Sousa, Joana A. Palha, Fernanda Marques
    Progress in Neurobiology.2015; 131: 120.     CrossRef
Increased Selenoprotein P Levels in Subjects with Visceral Obesity and Nonalcoholic Fatty Liver Disease
Hae Yoon Choi, Soon Young Hwang, Chang Hee Lee, Ho Cheol Hong, Sae Jeong Yang, Hye Jin Yoo, Ji A Seo, Sin Gon Kim, Nan Hee Kim, Sei Hyun Baik, Dong Seop Choi, Kyung Mook Choi
Diabetes Metab J. 2013;37(1):63-71.   Published online February 15, 2013
DOI: https://doi.org/10.4093/dmj.2013.37.1.63
  • 5,891 View
  • 42 Download
  • 90 Crossref
AbstractAbstract PDFPubReader   
Background

Selenoprotein P (SeP) has recently been reported as a novel hepatokine that regulates insulin resistance and systemic energy metabolism in rodents and humans. We explored the associations among SeP, visceral obesity, and nonalcoholic fatty liver disease (NAFLD).

Methods

We examined serum SeP concentrations in subjects with increased visceral fat area (VFA) or liver fat accumulation measured with computed tomography. Our study subjects included 120 nondiabetic individuals selected from participants of the Korean Sarcopenic Obesity Study. In addition, we evaluated the relationship between SeP and cardiometabolic risk factors, including homeostasis model of insulin resistance (HOMA-IR), high sensitivity C-reactive protein (hsCRP), adiponectin values, and brachial-ankle pulse wave velocity (baPWV).

Results

Subjects with NAFLD showed increased levels of HOMA-IR, hsCRP, VFA, and several components of metabolic syndrome and decreased levels of adiponectin and high density lipoprotein cholesterol than those of controls. Serum SeP levels were positively correlated with VFA, hsCRP, and baPWV and negatively correlated with the liver attenuation index. Not only subjects with visceral obesity but also those with NAFLD exhibited significantly increased SeP levels (P<0.001). In multiple logistic regression analysis, the subjects in the highest SeP tertile showed a higher risk for NAFLD than those in the lowest SeP tertile, even after adjusting for potential confounding factors (odds ratio, 7.48; 95% confidence interval, 1.72 to 32.60; P=0.007).

Conclusion

Circulating SeP levels were increased in subjects with NAFLD as well as in those with visceral obesity and may be a novel biomarker for NAFLD.

Citations

Citations to this article as recorded by  
  • Inhibition of selenium supply function of selenoprotein p through adduct formation by sulforaphane
    Xinying Ye, Takashi Toyama, Wang Yinuo, Runa Kudo, Siu Stephanie, Kotoko Arisawa, Yoshiro Saito
    The Journal of Nutritional Biochemistry.2025; 135: 109781.     CrossRef
  • Myosteatosis: Diagnosis, pathophysiology and consequences in metabolic dysfunction-associated steatotic liver disease
    Guillaume Henin, Audrey Loumaye, Isabelle A. Leclercq, Nicolas Lanthier
    JHEP Reports.2024; 6(2): 100963.     CrossRef
  • Association between serum trace element, mineral, and amino acid levels with non-alcoholic fatty liver disease (NAFLD) in adult women
    Alexey A. Tinkov, Tatiana V. Korobeinikova, Galina D. Morozova, Michael Aschner, Daria V. Mak, Abel Santamaria, Joao B.T. Rocha, Tatiana I. Sotnikova, Serafima Ia. Tazina, Anatoly V. Skalny
    Journal of Trace Elements in Medicine and Biology.2024; 83: 127397.     CrossRef
  • Adipose-derived extracellular vesicles – a novel cross-talk mechanism in insulin resistance, non-alcoholic fatty liver disease, and polycystic ovary syndrome
    Dušan Mladenović, Milena Vesković, Nikola Šutulović, Dragan Hrnčić, Olivera Stanojlović, Lena Radić, Jelica Bjekić Macut, Djuro Macut
    Endocrine.2024; 85(1): 18.     CrossRef
  • Association of metabolic-dysfunction associated steatotic liver disease with polycystic ovary syndrome
    Qiuyu Xu, Jie Zhang, Yan Lu, Ling Wu
    iScience.2024; 27(2): 108783.     CrossRef
  • Selenium biomarkers and miR‐7‐5p in overweight/obese women
    Higor Paiva de Mendonça Alves, Graziela Biude Silva Duarte, Adriano Carlos de Souza Junior, Leonam da Silva Pereira Batista, Marcelo Macedo Rogero, Fernando Barbosa Jr, Silvia Maria Franciscato Cozzolino, Raquel Costa Silva Dantas-Komatsu, Karina Zaira Si
    Journal of Trace Elements in Medicine and Biology.2024; 86: 127499.     CrossRef
  • Deciphering the associations of selenium distribution in serum GPx-3 and selenoprotein P with cardiovascular risk factors in a healthy population with moderate levels of selenium: The ATTICA study
    Sophia Letsiou, Evangelia Damigou, Tzortzis Nomikos, Spiros A. Pergantis, Christos Pitsavos, Demosthenes Panagiotakos, Smaragdi Antonopoulou
    Journal of Trace Elements in Medicine and Biology.2024; 86: 127509.     CrossRef
  • Association Between Serum Remnant Cholesterol Level and Metabolic Dysfunction-associated Steatotic Liver Histology
    Teruki Miyake, Shinya Furukawa, Bunzo Matsuura, Osamu Yoshida, Ayumi Kanamoto, Masumi Miyazaki, Akihito Shiomi, Hironobu Nakaguchi, Yuki Okazaki, Yoshiko Nakamura, Yusuke Imai, Mitsuhito Koizumi, Takao Watanabe, Yasunori Yamamoto, Yohei Koizumi, Yoshio To
    The Journal of Clinical Endocrinology & Metabolism.2024;[Epub]     CrossRef
  • The role of hepatokines in NAFLD
    Norbert Stefan, Fritz Schick, Andreas L. Birkenfeld, Hans-Ulrich Häring, Morris F. White
    Cell Metabolism.2023; 35(2): 236.     CrossRef
  • The regulatory role of metabolic organ-secreted factors in the nonalcoholic fatty liver disease and cardiovascular disease
    Li Qin, Junru Wu, Xuejing Sun, Xuewei Huang, Wei Huang, Chunyan Weng, Jingjing Cai
    Frontiers in Cardiovascular Medicine.2023;[Epub]     CrossRef
  • The Role of Organokines in Obesity and Type 2 Diabetes and Their Functions as Molecular Transducers of Nutrition and Exercise
    Ji Ye Lim, Eunju Kim
    Metabolites.2023; 13(9): 979.     CrossRef
  • Hepatokine Profile in Adolescents with Polycystic Ovary Syndrome: A Case–Control Study
    Aikaterini Giannouli, Charikleia Stefanaki, Christos Kouskoutis, Marianna Konidari, Iliana Mani, Konstantina Konidari, Sophia L. Markantonis, Aimilia Mantzou, Spyridon P. Dourakis, Efthymios Deligeoroglou, Flora Bacopoulou
    Journal of Clinical Medicine.2023; 12(17): 5744.     CrossRef
  • The Interconnection between Hepatic Insulin Resistance and Metabolic Dysfunction-Associated Steatotic Liver Disease—The Transition from an Adipocentric to Liver-Centric Approach
    Milena Vesković, Nikola Šutulović, Dragan Hrnčić, Olivera Stanojlović, Djuro Macut, Dušan Mladenović
    Current Issues in Molecular Biology.2023; 45(11): 9084.     CrossRef
  • Sulforaphane decreases serum selenoprotein P levels through enhancement of lysosomal degradation independent of Nrf2
    Xinying Ye, Takashi Toyama, Keiko Taguchi, Kotoko Arisawa, Takayuki Kaneko, Ryouhei Tsutsumi, Masayuki Yamamoto, Yoshiro Saito
    Communications Biology.2023;[Epub]     CrossRef
  • “Alphabet” Selenoproteins: Implications in Pathology
    Carmen Beatrice Dogaru, Carmen Duță, Corina Muscurel, Irina Stoian
    International Journal of Molecular Sciences.2023; 24(20): 15344.     CrossRef
  • Metabolic dysfunction-associated steatotic liver disease and the heart
    Stan Driessen, Sven M. Francque, Stefan D. Anker, Manuel Castro Cabezas, Diederick E. Grobbee, Maarten E. Tushuizen, Adriaan G. Holleboom
    Hepatology.2023;[Epub]     CrossRef
  • The effect of High-intensity interval training with Portulaca oleracea Hydroalcoholic extract on gene expression of Selenoprotein P (SeP) and insulin resistance in rats with nonalcoholic fatty liver
    Zohre Hosseini, Sadegh Cheragh-Birjandi
    Journal of Birjand University of Medical Sciences.2023; 30(3): 257.     CrossRef
  • Associations between Circulating SELENOP Level and Disorders of Glucose and Lipid Metabolism: A Meta-Analysis
    Ruirui Yu, Zhoutian Wang, Miaomiao Ma, Ping Xu, Longjian Liu, Alexey A. Tinkov, Xin Gen Lei, Ji-Chang Zhou
    Antioxidants.2022; 11(7): 1263.     CrossRef
  • Contribution of organokines in the development of NAFLD/NASH associated hepatocellular carcinoma
    Meenakshi Vachher, Savita Bansal, Bhupender Kumar, Sandeep Yadav, Taruna Arora, Nalini Moza Wali, Archana Burman
    Journal of Cellular Biochemistry.2022; 123(10): 1553.     CrossRef
  • Regulatory network and interplay of hepatokines, stellakines, myokines and adipokines in nonalcoholic fatty liver diseases and nonalcoholic steatohepatitis
    Bing Yang, Liqing Lu, Dongmei Zhou, Wei Fan, Lucía Barbier-Torres, Justin Steggerda, Heping Yang, Xi Yang
    Frontiers in Endocrinology.2022;[Epub]     CrossRef
  • Cytokines and regulation of glucose and lipid metabolism in the obesity
    V. I. Scherbakov, G. A. Skosyreva, T. I. Ryabichenko, O. O. Obukhova
    Obesity and metabolism.2022; 19(3): 317.     CrossRef
  • SeP is elevated in NAFLD and participates in NAFLD pathogenesis through AMPK/ACC pathway
    Yi Chen, Xinjue He, Xueyang Chen, Youming Li, Yini Ke
    Journal of Cellular Physiology.2021; 236(5): 3800.     CrossRef
  • Hepatokines and metabolism: Deciphering communication from the liver
    Sharon O. Jensen-Cody, Matthew J. Potthoff
    Molecular Metabolism.2021; 44: 101138.     CrossRef
  • Weight-loss-independent benefits of exercise on liver steatosis and stiffness in Japanese men with NAFLD
    Sechang Oh, Takehiko Tsujimoto, Bokun Kim, Fumihiko Uchida, Hideo Suzuki, Seiichiro Iizumi, Tomonori Isobe, Takeji Sakae, Kiyoji Tanaka, Junichi Shoda
    JHEP Reports.2021; 3(3): 100253.     CrossRef
  • Efficacy of Weight Reduction on Pediatric Nonalcoholic Fatty Liver Disease: Opportunities to Improve Treatment Outcomes Through Pharmacotherapy
    Chance S. Friesen, Chelsea Hosey-Cojocari, Sherwin S. Chan, Iván L. Csanaky, Jonathan B. Wagner, Brooke R. Sweeney, Alec Friesen, Jason D. Fraser, Valentina Shakhnovich
    Frontiers in Endocrinology.2021;[Epub]     CrossRef
  • Association of Urinary and Dietary Selenium and of Serum Selenium Species with Serum Alanine Aminotransferase in a Healthy Italian Population
    Teresa Urbano, Tommaso Filippini, Daniela Lasagni, Tiziana De Luca, Peter Grill, Sabrina Sucato, Elisa Polledri, Guy Djeukeu Noumbi, Marcella Malavolti, Annalisa Santachiara, Thelma A. Pertinhez, Roberto Baricchi, Silvia Fustinoni, Bernhard Michalke, Marc
    Antioxidants.2021; 10(10): 1516.     CrossRef
  • Selenotranscriptome Network in Non-alcoholic Fatty Liver Disease
    Kaitlin Day, Lucia A. Seale, Ross M. Graham, Barbara R. Cardoso
    Frontiers in Nutrition.2021;[Epub]     CrossRef
  • Hepatokines and Non-Alcoholic Fatty Liver Disease: Linking Liver Pathophysiology to Metabolism
    Tae Hyun Kim, Dong-Gyun Hong, Yoon Mee Yang
    Biomedicines.2021; 9(12): 1903.     CrossRef
  • Leukocyte cell-derived chemotaxin-2 and fibroblast growth factor 21 in alcohol-induced liver cirrhosis
    Jarosław Jerzy Sak, Andrzej Prystupa, Paweł Kiciński, Dorota Luchowska-Kocot, Ewa Kurys-Denis, Hanna Bis-Wencel
    World Journal of Hepatology.2021; 13(12): 2071.     CrossRef
  • Acute Hyperenergetic, High-Fat Feeding Increases Circulating FGF21, LECT2, and Fetuin-A in Healthy Men
    Scott A Willis, Jack A Sargeant, Thomas Yates, Toshinari Takamura, Hiroaki Takayama, Vinay Gupta, Emily Brittain, Joe Crawford, Siôn A Parry, Alice E Thackray, Veronica Varela-Mato, David J Stensel, Rachel M Woods, Carl J Hulston, Guruprasad P Aithal, Jam
    The Journal of Nutrition.2020; 150(5): 1076.     CrossRef
  • Targeting fibrinogen‐like protein 1 is a novel therapeutic strategy to combat obesity
    Hung‐Tsung Wu, Szu‐Chi Chen, Kang‐Chih Fan, Chun‐Heng Kuo, Shin‐Yu Lin, Shu‐Huei Wang, Chih‐Jen Chang, Hung‐Yuan Li
    The FASEB Journal.2020; 34(2): 2958.     CrossRef
  • Nonalcoholic fatty liver disease and cardiovascular disease phenotypes
    Giandomenico Bisaccia, Fabrizio Ricci, Cesare Mantini, Claudio Tana, Gian Luca Romani, Cosima Schiavone, Sabina Gallina
    SAGE Open Medicine.2020;[Epub]     CrossRef
  • Higher Serum Selenoprotein P Level as a Novel Inductor of Metabolic Complications in Psoriasis
    Anna Baran, Julia Nowowiejska, Julita Anna Krahel, Tomasz W. Kaminski, Magdalena Maciaszek, Iwona Flisiak
    International Journal of Molecular Sciences.2020; 21(13): 4594.     CrossRef
  • The Role of Exercise in the Interplay between Myokines, Hepatokines, Osteokines, Adipokines, and Modulation of Inflammation for Energy Substrate Redistribution and Fat Mass Loss: A Review
    Adrian M. Gonzalez-Gil, Leticia Elizondo-Montemayor
    Nutrients.2020; 12(6): 1899.     CrossRef
  • Selenoprotein P; P for Plasma, Prognosis, Prophylaxis, and More
    Ryouhei Tsutsumi, Yoshiro Saito
    Biological and Pharmaceutical Bulletin.2020; 43(3): 366.     CrossRef
  • Selenium and selenoprotein P in nonalcoholic fatty liver disease
    Stergios A. Polyzos, Jannis Kountouras, Antonis Goulas, Leonidas Duntas
    Hormones.2020; 19(1): 61.     CrossRef
  • The Effects of Endoplasmic-Reticulum-Resident Selenoproteins in a Nonalcoholic Fatty Liver Disease Pig Model Induced by a High-Fat Diet
    Pengzu Wang, Zhuang Lu, Meng He, Baoming Shi, Xingen Lei, Anshan Shan
    Nutrients.2020; 12(3): 692.     CrossRef
  • The risk of pregnancy‐associated hypertension in women with nonalcoholic fatty liver disease
    Young Mi Jung, Seung Mi Lee, Subeen Hong, Ja Nam Koo, Ig Hwan Oh, Byoung Jae Kim, Sun Min Kim, Sang Youn Kim, Gyoung Min Kim, Sae Kyung Joo, Sue Shin, Errol R. Norwitz, Chan‐Wook Park, Jong Kwan Jun, Won Kim, Joong Shin Park
    Liver International.2020; 40(10): 2417.     CrossRef
  • Why Multiples of 21? Why does Selenoprotein P Contain Multiple Selenocysteine Residues?
    Janinah Baclaocos, John James Mackrill
    Current Nutraceuticals.2020; 1(1): 42.     CrossRef
  • Selenium and Selenoproteins in Adipose Tissue Physiology and Obesity
    Alexey A. Tinkov, Olga P. Ajsuvakova, Tommaso Filippini, Ji-Chang Zhou, Xin Gen Lei, Eugenia R. Gatiatulina, Bernhard Michalke, Margarita G. Skalnaya, Marco Vinceti, Michael Aschner, Anatoly V. Skalny
    Biomolecules.2020; 10(4): 658.     CrossRef
  • Metabolic adaptations after bariatric surgery: adipokines, myokines and hepatokines
    Justine Faramia, Giada Ostinelli, Virginie Drolet-Labelle, Frédéric Picard, André Tchernof
    Current Opinion in Pharmacology.2020; 52: 67.     CrossRef
  • Physiopathology of Lifestyle Interventions in Non-Alcoholic Fatty Liver Disease (NAFLD)
    David Carneros, Guillermo López-Lluch, Matilde Bustos
    Nutrients.2020; 12(11): 3472.     CrossRef
  • Interplay between Oxidative Stress and Metabolic Derangements in Non-Alcoholic Fatty Liver Disease: The Role of Selenoprotein P
    Gian Paolo Caviglia, Chiara Rosso, Angelo Armandi, Melania Gaggini, Fabrizia Carli, Maria Lorena Abate, Antonella Olivero, Davide Giuseppe Ribaldone, Giorgio Maria Saracco, Amalia Gastaldelli, Elisabetta Bugianesi
    International Journal of Molecular Sciences.2020; 21(22): 8838.     CrossRef
  • Can hepatokines be regarded as novel non-invasive serum biomarkers of intrahepatic lipid content in obese children?
    Marta Flisiak-Jackiewicz, Anna Bobrus-Chociej, Natalia Wasilewska, Eugeniusz Tarasow, Malgorzata Wojtkowska, Dariusz Marek Lebensztejn
    Advances in Medical Sciences.2019; 64(2): 280.     CrossRef
  • Dietary pattern associated with selenoprotein P and MRI-derived body fat volumes, liver signal intensity, and metabolic disorders
    Romina di Giuseppe, Sandra Plachta-Danielzik, Manja Koch, Ute Nöthlings, Sabrina Schlesinger, Jan Borggrefe, Marcus Both, Hans-Peter Müller, Jan Kassubek, Gunnar Jacobs, Wolfgang Lieb
    European Journal of Nutrition.2019; 58(3): 1067.     CrossRef
  • Cytokines and Abnormal Glucose and Lipid Metabolism
    Jie Shi, Jiangao Fan, Qing Su, Zhen Yang
    Frontiers in Endocrinology.2019;[Epub]     CrossRef
  • Role of exercise-induced hepatokines in metabolic disorders
    Gaël Ennequin, Pascal Sirvent, Martin Whitham
    American Journal of Physiology-Endocrinology and Metabolism.2019; 317(1): E11.     CrossRef
  • Metabolomics signature associated with circulating serum selenoprotein P levels
    Romina di Giuseppe, Manja Koch, Ute Nöthlings, Gabi Kastenmüller, Anna Artati, Jerzy Adamski, Gunnar Jacobs, Wolfgang Lieb
    Endocrine.2019; 64(3): 486.     CrossRef
  • Secretomics to Discover Regulators in Diseases
    Parkyong Song, Yonghoon Kwon, Jae-Yeol Joo, Do-Geun Kim, Jong Hyuk Yoon
    International Journal of Molecular Sciences.2019; 20(16): 3893.     CrossRef
  • Impact of Lipotoxicity on Tissue “Cross Talk” and Metabolic Regulation
    Magdalene K. Montgomery, William De Nardo, Matthew J. Watt
    Physiology.2019; 34(2): 134.     CrossRef
  • The Liver as an Endocrine Organ—Linking NAFLD and Insulin Resistance
    Matthew J Watt, Paula M Miotto, William De Nardo, Magdalene K Montgomery
    Endocrine Reviews.2019; 40(5): 1367.     CrossRef
  • Inter-organ cross-talk in metabolic syndrome
    Christina Priest, Peter Tontonoz
    Nature Metabolism.2019; 1(12): 1177.     CrossRef
  • Serum selenoprotein P, but not selenium, predicts future hyperglycemia in a general Japanese population
    Swe Mar Oo, Hirofumi Misu, Yoshiro Saito, Mutsumi Tanaka, Seiji Kato, Yuki Kita, Hiroaki Takayama, Yumie Takeshita, Takehiro Kanamori, Toru Nagano, Masatoshi Nakagen, Takeshi Urabe, Naoto Matsuyama, Shuichi Kaneko, Toshinari Takamura
    Scientific Reports.2018;[Epub]     CrossRef
  • NAFLD and cardiovascular disease
    Elisabete Martins, Ana Oliveira
    Porto Biomedical Journal.2018; 3(2): e2.     CrossRef
  • The influence of adiposity and acute exercise on circulating hepatokines in normal-weight and overweight/obese men
    Jack A. Sargeant, Guruprasad P. Aithal, Toshinari Takamura, Hirofumi Misu, Hiroaki Takayama, Jessica A. Douglas, Mark C. Turner, David J. Stensel, Myra A. Nimmo, David R. Webb, Thomas Yates, James A. King
    Applied Physiology, Nutrition, and Metabolism.2018; 43(5): 482.     CrossRef
  • Low Urine pH Is Associated with Non-alcoholic Fatty Liver Disease: A Community-based Cross-sectional Study
    Teruki Miyake, Sakiko Yoshida, Shin Yamamoto, Shinya Furukawa, Osamu Yoshida, Sayaka Kanzaki, Hidenori Senba, Toru Ishihara, Mitsuhito Koizumi, Yoshio Tokumoto, Masashi Hirooka, Teru Kumagi, Masanori Abe, Kohichiro Kitai, Bunzo Matsuura, Yoichi Hiasa
    Internal Medicine.2018; 57(19): 2799.     CrossRef
  • Evaluation of endothelial dysfunction in patients with nonalcoholic fatty liver disease: Association of selenoprotein P with carotid intima-media thickness and endothelium-dependent vasodilation
    Ibrahim Cetindağlı, Muammer Kara, Alpaslan Tanoglu, Veysel Ozalper, Serkan Aribal, Yusuf Hancerli, Mehmet Unal, Onur Ozarı, Serdar Hira, Mustafa Kaplan, Yusuf Yazgan
    Clinics and Research in Hepatology and Gastroenterology.2017; 41(5): 516.     CrossRef
  • Differences in the risk of fatty liver for onset of impaired fasting glucose according to baseline plasma glucose levels
    Teruki Miyake, Masashi Hirooka, Osamu Yoshida, Shinya Furukawa, Teru Kumagi, Mitsuhito Koizumi, Shin Yamamoto, Taira Kuroda, Eiji Arimitsu, Eiji Takeshita, Masanori Abe, Kohichiro Kitai, Bunzo Matsuura, Yoichi Hiasa
    Journal of Gastroenterology.2017; 52(2): 237.     CrossRef
  • Hepatokines: linking nonalcoholic fatty liver disease and insulin resistance
    Ruth C. R. Meex, Matthew J. Watt
    Nature Reviews Endocrinology.2017; 13(9): 509.     CrossRef
  • Circulating selenoprotein P levels in relation to MRI‐derived body fat volumes, liver fat content, and metabolic disorders
    Romina di Giuseppe, Manja Koch, Sabrina Schlesinger, Jan Borggrefe, Marcus Both, Hans‐Peter Müller, Jan Kassubek, Gunnar Jacobs, Ute Nöthlings, Wolfgang Lieb
    Obesity.2017; 25(6): 1128.     CrossRef
  • Eicosapentaenoic acid down-regulates expression of the selenoprotein P gene by inhibiting SREBP-1c protein independently of the AMP-activated protein kinase pathway in H4IIEC3 hepatocytes
    Natsumi Tajima-Shirasaki, Kiyo-aki Ishii, Hiroaki Takayama, Takayoshi Shirasaki, Hisakazu Iwama, Keita Chikamoto, Yoshiro Saito, Yasumasa Iwasaki, Atsushi Teraguchi, Fei Lan, Akihiro Kikuchi, Yumie Takeshita, Koji Murao, Seiichi Matsugo, Shuichi Kaneko, H
    Journal of Biological Chemistry.2017; 292(26): 10791.     CrossRef
  • Selenoprotein P is elevated in individuals with obesity, but is not independently associated with insulin resistance
    Miaoxin Chen, Bo Liu, David Wilkinson, Amy T. Hutchison, Campbell H. Thompson, Gary A. Wittert, Leonie K. Heilbronn
    Obesity Research & Clinical Practice.2017; 11(2): 227.     CrossRef
  • Cardiovascular Risk in Patients with Non-alcoholic Fatty Liver Disease
    Hak Soo Kim, Yong Kyun Cho
    The Korean Journal of Gastroenterology.2017; 69(6): 333.     CrossRef
  • Association between betatrophin/ANGPTL8 and non-alcoholic fatty liver disease: animal and human studies
    Yong-ho Lee, Sang-Guk Lee, Chan Joo Lee, Soo Hyun Kim, Young-Mi Song, Mi Ra Yoon, Byung Hun Jeon, Jae Hyuk Lee, Byung-Wan Lee, Eun Seok Kang, Hyun Chul Lee, Bong-Soo Cha
    Scientific Reports.2016;[Epub]     CrossRef
  • Implication of hepatokines in metabolic disorders and cardiovascular diseases
    Tae Woo Jung, Hye Jin Yoo, Kyung Mook Choi
    BBA Clinical.2016; 5: 108.     CrossRef
  • Selenoproteins: Antioxidant selenoenzymes and beyond
    Holger Steinbrenner, Bodo Speckmann, Lars-Oliver Klotz
    Archives of Biochemistry and Biophysics.2016; 595: 113.     CrossRef
  • Metabolic Adaptation in Obesity and Type II Diabetes: Myokines, Adipokines and Hepatokines
    Kyoung-Jin Oh, Da Lee, Won Kim, Baek Han, Sang Lee, Kwang-Hee Bae
    International Journal of Molecular Sciences.2016; 18(1): 8.     CrossRef
  • Pathogenesis of nonalcoholic steatohepatitis
    Wensheng Liu, Robert D. Baker, Tavleen Bhatia, Lixin Zhu, Susan S. Baker
    Cellular and Molecular Life Sciences.2016; 73(10): 1969.     CrossRef
  • Stéatose et résistance à l’insuline : implication des hépatokines
    C. Bertrand, P. Valet, I. Castan-Laurell
    Obésité.2016; 11(3): 170.     CrossRef
  • Pathophysiology of Non Alcoholic Fatty Liver Disease
    Salvatore Petta, Amalia Gastaldelli, Eleni Rebelos, Elisabetta Bugianesi, Piergiorgio Messa, Luca Miele, Gianluca Svegliati-Baroni, Luca Valenti, Ferruccio Bonino
    International Journal of Molecular Sciences.2016; 17(12): 2082.     CrossRef
  • Alterations in serum levels of fetuin A and selenoprotein P in chronic hepatitis C patients with concomitant type 2 diabetes: A case-control study
    Sahar A. Ali, Walaa M.H. Nassif, Dalia H.A. Abdelaziz
    Clinics and Research in Hepatology and Gastroenterology.2016; 40(4): 465.     CrossRef
  • Non-alcoholic fatty liver disease and cardiovascular risk: Pathophysiological mechanisms and implications
    Sven M. Francque, Denise van der Graaff, Wilhelmus J. Kwanten
    Journal of Hepatology.2016; 65(2): 425.     CrossRef
  • “Omics” of Selenium Biology: A Prospective Study of Plasma Proteome Network Before and After Selenized-Yeast Supplementation in Healthy Men
    Indu Sinha, Kubra Karagoz, Rachel L. Fogle, Christopher S. Hollenbeak, Arnold H. Zea, Kazim Y. Arga, Anne E. Stanley, Wayne C. Hawkes, Raghu Sinha
    OMICS: A Journal of Integrative Biology.2016; 20(4): 202.     CrossRef
  • Nonalcoholic steatohepatitis is strongly associated with sarcopenic obesity in patients with cirrhosis undergoing liver transplant evaluation
    Sandra Carias, Ana Lia Castellanos, Valery Vilchez, Rashmi Nair, Anna Christina Dela Cruz, Jennifer Watkins, Terrence Barrett, Patel Trushar, Karyn Esser, Roberto Gedaly
    Journal of Gastroenterology and Hepatology.2016; 31(3): 628.     CrossRef
  • Variants in Genes Controlling Oxidative Metabolism Contribute to Lower Hepatic ATP Independent of Liver Fat Content in Type 1 Diabetes
    Sofiya Gancheva, Alessandra Bierwagen, Kirti Kaul, Christian Herder, Peter Nowotny, Sabine Kahl, Guido Giani, Birgit Klueppelholz, Birgit Knebel, Paul Begovatz, Klaus Strassburger, Hadi Al-Hasani, Jesper Lundbom, Julia Szendroedi, Michael Roden
    Diabetes.2016; 65(7): 1849.     CrossRef
  • Selenoprotein P is not elevated in gestational diabetes mellitus
    Alev E. Altinova, Ozlem T. Iyidir, Cigdem Ozkan, Damla Ors, Merve Ozturk, Ozlem Gulbahar, Nuray Bozkurt, Fusun B. Toruner, Mujde Akturk, Nuri Cakir, Metin Arslan
    Gynecological Endocrinology.2015; 31(11): 874.     CrossRef
  • Selenium and Human Health: Witnessing a Copernican Revolution?
    Ewa Jablonska, Marco Vinceti
    Journal of Environmental Science and Health, Part C.2015; 33(3): 328.     CrossRef
  • Toenail selenium and risk of type 2 diabetes: the ORDET cohort study
    Marco Vinceti, Sara Grioni, Dorothea Alber, Dario Consonni, Carlotta Malagoli, Claudia Agnoli, Marcella Malavolti, Valeria Pala, Vittorio Krogh, Sabina Sieri
    Journal of Trace Elements in Medicine and Biology.2015; 29: 145.     CrossRef
  • Expression of Selenoprotein Genes Is Affected by Obesity of Pigs Fed a High-Fat Diet
    Hua Zhao, Ke Li, Jia-Yong Tang, Ji-Chang Zhou, Kang-Ning Wang, Xin-Jie Xia, Xin Gen Lei
    The Journal of Nutrition.2015; 145(7): 1394.     CrossRef
  • Hepatokines as a Link between Obesity and Cardiovascular Diseases
    Hye Jin Yoo, Kyung Mook Choi
    Diabetes & Metabolism Journal.2015; 39(1): 10.     CrossRef
  • The Dipeptidyl Peptidase-4 Inhibitor Teneligliptin Attenuates Hepatic Lipogenesis via AMPK Activation in Non-Alcoholic Fatty Liver Disease Model Mice
    Takayasu Ideta, Yohei Shirakami, Tsuneyuki Miyazaki, Takahiro Kochi, Hiroyasu Sakai, Hisataka Moriwaki, Masahito Shimizu
    International Journal of Molecular Sciences.2015; 16(12): 29207.     CrossRef
  • Dietary selenate attenuates adiposity and improves insulin sensitivity in high-fat diet-induced obese mice
    Choon Young Kim, Yuyan Zhu, Kimberly K. Buhman, Kee-Hong Kim
    Journal of Functional Foods.2015; 17: 33.     CrossRef
  • Use of a Diabetes Self-Assessment Score to Predict Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis
    Gyuri Kim, Yong-ho Lee, Young Min Park, Jungghi Kim, Heesuk Kim, Byung-Wan Lee, Eun Seok Kang, Bong-Soo Cha, Hyun Chul Lee, Dae Jung Kim
    Medicine.2015; 94(27): e1103.     CrossRef
  • Inhibition of SH2-domain-containing inositol 5-phosphatase (SHIP2) ameliorates palmitate induced-apoptosis through regulating Akt/FOXO1 pathway and ROS production in HepG2 cells
    Sattar Gorgani-Firuzjaee, Khosrow Adeli, Reza Meshkani
    Biochemical and Biophysical Research Communications.2015; 464(2): 441.     CrossRef
  • Exendin-4 Inhibits the Expression of SEPP1 and Fetuin-A via Improvement of Palmitic Acid-Induced Endoplasmic Reticulum Stress by AMPK
    Jinmi Lee, Seok-Woo Hong, Se Eun Park, Eun-Jung Rhee, Cheol-Young Park, Ki-Won Oh, Sung-Woo Park, Won-Young Lee
    Endocrinology and Metabolism.2015; 30(2): 177.     CrossRef
  • AMPK activator-mediated inhibition of endoplasmic reticulum stress ameliorates carrageenan-induced insulin resistance through the suppression of selenoprotein P in HepG2 hepatocytes
    Tae Woo Jung, So Young Lee, Ho Cheol Hong, Hae Yoon Choi, Hye Jin Yoo, Sei Hyun Baik, Kyung Mook Choi
    Molecular and Cellular Endocrinology.2014; 382(1): 66.     CrossRef
  • HIF‐1α Expression as a Protective Strategy of HepG2 Cells Against Fatty Acid‐Induced Toxicity
    Wonbaek Yoo, Kyung Hee Noh, Jae Hee Ahn, Ji Hee Yu, Ji A. Seo, Sin Gon Kim, Kyung Mook Choi, Sei Hyun Baik, Dong Seop Choi, Tae Woo Kim, Hyo Joon Kim, Nan Hee Kim
    Journal of Cellular Biochemistry.2014; 115(6): 1147.     CrossRef
  • Genetic variants in selenoprotein P plasma 1 gene (SEPP1) are associated with fasting insulin and first phase insulin response in Hispanics
    Jacklyn N. Hellwege, Nicholette D. Palmer, Julie T. Ziegler, Carl D. Langefeld, Carlos Lorenzo, Jill M. Norris, Toshinari Takamura, Donald W. Bowden
    Gene.2014; 534(1): 33.     CrossRef
  • Levels of circulating selenoprotein P, fibroblast growth factor (FGF) 21 and FGF23 in relation to the metabolic syndrome in young children
    B-J Ko, S M Kim, K H Park, H S Park, C S Mantzoros
    International Journal of Obesity.2014; 38(12): 1497.     CrossRef
  • The association between non-alcoholic fatty liver disease and carotid atherosclerosis in subjects with within-reference range alanine aminotransferase levels
    Kyung-Soo Kim, Hyun-Ju Oh, Dae-Jung Kim, Soo-Kyung Kim, Seok Won Park, Yong-Wook Cho, Kap-Bum Huh
    Endocrine Journal.2013; 60(12): 1295.     CrossRef
Effect of Eplerenone, a Selective Aldosterone Blocker, on the Development of Diabetic Nephropathy in Type 2 Diabetic Rats
Jae Hee Ahn, Ho Cheol Hong, Myong Jin Cho, Yoon Jung Kim, Hae Yoon Choi, Chai Ryoung Eun, Sae Jeong Yang, Hye Jin Yoo, Hee Young Kim, Ji A Seo, Sin Gon Kim, Kyung Mook Choi, Sei Hyun Baik, Dong Seop Choi, Nan Hee Kim
Diabetes Metab J. 2012;36(2):128-135.   Published online April 17, 2012
DOI: https://doi.org/10.4093/dmj.2012.36.2.128
  • 4,805 View
  • 38 Download
  • 9 Crossref
AbstractAbstract PDFPubReader   
Background

Aldosterone antagonists are reported to have beneficial effects on diabetic nephropathy by effective blocking of the renin-angiotensin-aldosterone system. We investigated the renoprotective effect of the selective aldosterone receptor blocker eplerenone, the angiotensin converting enzyme inhibitor lisinopril, and combined eplerenone and lisinopril treatment in type 2 diabetic rats.

Methods

Animals were divided into six groups as follows: Otsuka Long-Evans Tokushima Fatty (OLETF) rat control, OLETF rats treated with a low dose of eplerenone (50 mg/kg/day), OLETF rats treated with a high dose of eplerenone (200 mg/kg/day), OLETF rats treated with lisinopril (10 mg/kg/day), OLETF rats treated with a combination of both drugs (eplerenone 200 mg/kg/day and lisinopril 10 mg/kg/day), and obese non-diabetic Long-Evans Tokushima Otsuka rats for 26 weeks.

Results

Urinary albumin excretion was significantly lower in the lisinopril group, but not in the eplerenone group. Urinary albumin excretion was decreased in the combination group than in the lisinopril group. Glomerulosclerosis and renal expression of type I and type IV collagen, plasminogen activator inhibitor-1, transforming growth factor-β1, connective tissue growth factor, and fibronectin mRNA were markedly decreased in the lisinopril, eplerenone, and combination groups.

Conclusion

Eplerenone and lisinopril combination showed additional benefits on type 2 diabetic nephropathy compared to monotherapy of each drug.

Citations

Citations to this article as recorded by  
  • Up-Date on Diabetic Nephropathy
    Maria Chiara Pelle, Michele Provenzano, Marco Busutti, Clara Valentina Porcu, Isabella Zaffina, Lucia Stanga, Franco Arturi
    Life.2022; 12(8): 1202.     CrossRef
  • The role of free radical oxidation in the kidneys in the nephroprotective action of eplerenone, a mineralocorticoid receptor antagonist, in experimental diabetes mellitus
    A. Yu. Zharikov, S. O. Filinova, O. N. Mazko, O. G. Makarova, I. P. Bobrov, V. M. Bryukhanov
    Bulletin of Siberian Medicine.2021; 20(2): 29.     CrossRef
  • Effect of Mineralocorticoid Receptor Antagonism and ACE Inhibition on Angiotensin Profiles in Diabetic Kidney Disease: An Exploratory Study
    Johannes J. Kovarik, Christopher C. Kaltenecker, Oliver Domenig, Marlies Antlanger, Marko Poglitsch, Chantal Kopecky, Marcus D. Säemann
    Diabetes Therapy.2021; 12(9): 2485.     CrossRef
  • Diabetic nephropathy: An update on pathogenesis and drug development
    Vikram Rao A/L B Vasanth Rao, Sean Hong Tan, Mayuren Candasamy, Subrat Kumar Bhattamisra
    Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2019; 13(1): 754.     CrossRef
  • Effects of mineralocorticoid receptor antagonists on the progression of diabetic nephropathy
    Li‐Jing Sun, Yan‐Ni Sun, Jian‐Ping Shan, Geng‐Ru Jiang
    Journal of Diabetes Investigation.2017; 8(4): 609.     CrossRef
  • New agents modulating the renin-angiotensin-aldosterone system—Will there be a new therapeutic option?
    Anna Gromotowicz-Poplawska, Piotr Szoka, Patrycjusz Kolodziejczyk, Karol Kramkowski, Marzena Wojewodzka-Zelezniakowicz, Ewa Chabielska
    Experimental Biology and Medicine.2016; 241(17): 1888.     CrossRef
  • Crosstalk between peroxisome proliferator-activated receptor-γ and mineralcorticoid receptor in TNF-α activated renal tubular cell
    Jing Xiao, Weijun Chen, Yijun Lu, Xiaoli Zhang, Chensheng Fu, Zhenwen Yan, Zhenxing Zhang, Zhibin Ye
    Inflammation Research.2015; 64(8): 603.     CrossRef
  • Eplerenone reduces arterial thrombosis in diabetic rats
    Agnieszka Zakrzeska, Anna Gromotowicz-Popławska, Janusz Szemraj, Piotr Szoka, Wioleta Kisiel, Tomasz Purta, Irena Kasacka, Ewa Chabielska
    Journal of the Renin-Angiotensin-Aldosterone System.2015; 16(4): 1085.     CrossRef
  • Pharmacological modulation of fibrinolytic response – In vivo and in vitro studies
    Karol Kramkowski, Agnieszka Leszczynska, Wlodzimierz Buczko
    Pharmacological Reports.2015; 67(4): 695.     CrossRef

Diabetes Metab J : Diabetes & Metabolism Journal
Close layer
TOP